Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
752
datasets available to search
ShareScore release 0.9.0
Dataset results
752 results for “Osteoporosis”
Bone metabolism gene variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis
<p>This repository contains the raw and source data for the manuscript "Bone metabolism gene polymorphism and response to bisphosphonate treatment in women with postmenopausal osteoporosis" submitted to PLOS ONE.</p> <p><strong>Abstract: </strong></p> <p><em>Introduction:</em> Long-term treatment is used in patients with osteoporosis, and bisphosphonates (BPs) are the most commonly prescribed medications. However, in some patients this therapy is not effective, cause different side effects and complications. Unfortunately, at least one year is needed to identify and confirm an ineffectiveness of BPs therapy on bone mineral density (BMD). Among other factors, a response to BPs therapy may also be explained by genetic factors. The aim of this study was to analyze the influence of <em>SOST, PTH, FGF2, FDPS, GGPS1, </em>and<em> LRP5</em> gene polymorphisms on the response to treatment with BPs.</p> <p><em>Materials and methods: </em>Women with postmenopausal osteoporosis were included to this study if they used bisphosphonates for at least 12 months. Exclusion criteria were: persistence on BPs therapy less than 80%, bone metabolic diseases, diseases deemed to affect bone metabolism, malignant tumours, using of any medications influencing BMD. The study protocol was approved by the local ethics committee. The BMD at the lumbar spine and femoral neck were measured using dual x-ray absorptiometry (GE Lunar) before and at least 12 months after treatment with BPs. According to BMD change, patients were divided in two groups – responders and non-responders to BPs terapy. Polymorphic variants in <em>SOST, PTH, FGF2, FDPS, GGPS1, </em>and<em> LRP5</em> genes were determined using PCR analysis with TaqMan probes (Thermo Scientific).</p> <p><em>Results:</em> In total, 201 women with BPs therapy were included in the study. No statistically significant differences were observed in age, age at menopause, weight, height, BMI and baseline BMD levels between responders (122 subjects) and non-responders (79 subjects).</p> <p>As single markers, the <em>SOST </em>rs1234612 T/T (OR=2.3; P=0.02), <em>PTH</em> rs7125774 T/T (OR=2.8, P=0.0009), <em>FDPS</em> rs2297480 G/G (OR=29.3, P=2.2×10<sup>-7</sup>), and <em>GGPS1</em> rs10925503 C/C+C/T (OR=2.9; P=0.003) gene variants were over-represented in non-responders group. No significant association between <em>FGF2</em> rs6854081 and <em>LRP5</em> rs3736228 gene variants and response to BPs treatment was observed. The carriers of T-T-G-C allelic combination (constructed from rs1234612, rs7125774, rs2297480, and rs10925503) were predisposed to negative response to BPs treatment (OR = 4.9, 95% CI 1.7–14.6, P=0.005). The C-C-T-C combination was significantly over-represented in responders (OR = 0.1, 95% CI 0.1–0.5, P=0.006).</p> <p><em>Conclusions:</em> Our findings highlight the importance of identified single gene variants and their allelic combinations for pharmacogenetics of BPs therapy of osteoporosis. Complex screening of these genetic markers could be used as a new strategy for personalized antiresorptive therapy.</p>
Dataset: A Labeled Dataset for Osteoporosis Screening Based on Electromagnetic Attenuation
<p><strong>README</strong></p> <p><strong>Dataset name:</strong> osseus_dataset.csv </p> <p><strong>Version:</strong> 1.0 </p> <p><strong>Dataset period:</strong> 07/01/2021 - 09/31/2023</p> <p><strong>Dataset Characteristics:</strong> Multivalued </p> <p><strong>Number of Instances:</strong> 669</p> <p><strong>Number of Attributes:</strong> 31</p> <p><strong>Missing Values:</strong> yes</p> <p><strong>Area(s):</strong> Health and technology </p> <p><strong>Sources:</strong> </p> <ul> <li> <p>Electronic Patient Record (EPR) - University Hospital Onofre Lopes of Federal University of Rio Grande do Norte (HUOL/UFRN), Brazil;</p> </li> <li> <p>OSSEUS (Osteoporosis screening based on electromagnetic waves); and,</p> </li> <li> <p>DXA (Dual-energy x-ray absorptiometry). </p> </li> </ul> <p> </p> <p><strong>Description</strong>: The dataset “osseus_dataset.csv” (Table 1) contains elementary data related to risk factors and examinations performed by individuals in Rio Grande do Norte, Brazil, to investigate bone mineral density. Data were collected using the EPR of HUOL/UFRN, DXA, and OSSEUS, a low-cost device based on electromagnetic waves, which measures the attenuation of the signal when crossing the medial phalanx of the middle finger (PINHEIRO et al., 2021, ALBUQUERQUE et al., 2022).</p> <p><strong>Descrição</strong>: O conjunto de dados “osseus_dataset.csv” (Tabela 1) contém dados elementares relacionados a fatores de risco e exames realizados por indivíduos no Estado do Rio Grande do Norte, Brasil, para a investigação da densidade mineral óssea. Os dados foram coletados por meio do EPR do HUOL/UFRN, DXA e OSSEUS, um dispositivo de baixo custo baseado em ondas eletromagnéticas, que mede a atenuação do sinal ao atravessar a falange medial do dedo médio (PINHEIRO et al., 2021, ALBUQUERQUE et al., 2022).</p> <p> </p> <p><strong><strong>Table 1: </strong></strong>Description of Dataset Features.</p> <div> <table> <tbody> <tr> <td> <p><strong>Attributes</strong></p> </td> <td> <p><strong>Description</strong></p> </td> <td> <p><strong>datatype </strong></p> </td> <td> <p><strong>Value</strong></p> </td> </tr> <tr> <td> <p><strong>Electronic Patient Record (EPR)</strong></p> </td> </tr> <tr> <td> <p><strong>id</strong></p> </td> <td> <p>Unique identifier for a person (anonymous).</p> </td> <td> <p>Categorical. </p> </td> <td> <p>Person unique identifier.</p> </td> </tr> <tr> <td> <p><strong>gender</strong></p> </td> <td> <p>It informs the person's gender.</p> </td> <td> <p>Categorical.</p> </td> <td> <ul> <li> <p>female</p> </li> <li> <p>male</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>age</strong></p> </td> <td> <p>It informs the person's age.</p> </td> <td> <p>Numerical.</p> </td> <td> <p>Integer value for age</p> </td> </tr> <tr> <td> <p><strong>weight</strong></p> </td> <td> <p>Informs the value referring to the person's weight—the unit of mass in kilogram (kg).</p> </td> <td> <p>Numerical.</p> </td> <td> <p>Integer value for weight</p> </td> </tr> <tr> <td> <p><strong>height</strong></p> </td> <td> <p>Informs the value relating to the person's height—the unit of measurement for size in centimeters (cm).</p> </td> <td> <p>Numerical.</p> </td> <td> <p>Integer value for height</p> </td> </tr> <tr> <td> <p><strong>ethnicity</strong></p> </td> <td> <p>Informs the person's ethnicity.</p> </td> <td> <p>Categorical.</p> </td> <td> <ul> <li> <p>black</p> </li> <li> <p>brown</p> </li> <li> <p>white</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>target</strong></p> </td> <td> <p>Describe the person's diagnosis or medical report.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>normal</p> </li> <li> <p>osteoporosis</p> </li> <li> <p>low bone mineral density</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>alcohol</strong></p> </td> <td> <p>It informs whether the person consumes alcoholic beverages.</p> </td> <td> <p>Categorical.</p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>smoking</strong></p> </td> <td> <p>Informs whether the person is a smoker.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>activity</strong></p> </td> <td> <p>It informs whether the person practices physical activities.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>milk</strong></p> </td> <td> <p>It informs whether the person consumes dairy drinks.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>calcium</strong></p> </td> <td> <p>It informs whether the person uses calcium.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>vitamin_d</strong></p> </td> <td> <p>It informs whether the person uses Vitamin D.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>fall</strong></p> </td> <td> <p>It informs whether the person has a history of falling.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>parents_osteoporosis</strong></p> </td> <td> <p>It informs whether the person has a family history of osteoporosis.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>parents_curved</strong></p> </td> <td> <p>It informs whether the person has a family history of "parents curved."</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>corticosteroids</strong></p> </td> <td> <p>It informs whether the person uses corticosteroid-type medications for three months or longer.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>arthritis</strong></p> </td> <td> <p>Informs if the person has arthritis.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>diseases</strong></p> </td> <td> <p>Informs if the person has comorbidities.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>menopause</strong></p> </td> <td> <p>Informs if the person has menopause.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>testosterone</strong></p> </td> <td> <p>It informs whether the person uses testosterone.</p> </td> <td> <p>Categorical. </p> </td> <td> <ul> <li> <p>yes</p> </li> <li> <p>no</p> </li> </ul> </td> </tr> <tr> <td> <p><strong>OSSEUS (Osteoporosis screening based on electromagnetic waves)</strong></p> </td> </tr> <tr> <td> <p><strong>medial_length</strong></p> </td> <td> <p>Length of the medial phalanx in mm.</p> </td> <td> <p>Numerical. </p> </td> <td> <p>Integer value for length.</p> </td> </tr> <tr> <td> <p><strong>medial_height</strong></p> </td> <td> <p>Height of the medial phalanx in mm.</p> </td> <td> <p>Numerical.</p> </td> <td> <p>Integer value for height.</p> </td> </tr> <tr> <td> <p><strong>medial_width</strong></p> </td> <td> <p>Width of the medial phalanx in mm.</p> </td> <td> <p>Numerical.</p> </td> <td> <p>Integer value for width.</p> </td> </tr> <tr> <td> <p><strong>calibration</strong></p> </td> <td> <p>Osseus signal strength with no obstacle between the antennas.</p> </td> <td> <p>Numerical.</p> </td> <td> <p>Float value for calibration.</p> </td> </tr> <tr> <td> <p><strong>attenuation</strong></p> </td> <td> <p>Osseus signal strength with obstacles between antennas.</p> </td> <td> <p>Numerical.</p> </td> <td> <p>Float value for attenuation.</p> </td> </tr> <tr> <td> <p><strong>DXA (Dual-energy x-ray absorptiometry)</strong></p> </td> </tr> <tr> <td> <p><strong>spine_deviation</strong></p> </td> <td> <p>Reports the spinal standard deviation score that represents the difference between bone density and the expected value.</p> </td> <td> <p>Numerical. </p> </td> <td> <p>Float value for deviation.</p> </td> </tr> <tr> <td> <p><strong>femur_deviation</strong></p> </td> <td> <p>Reports the femur standard deviation score that represents the difference between bone density and the expected value.</p> </td> <td> <p>Numerical. </p> </td> <td> <p>Float value for deviation.</p> </td> </tr> <tr> <td> <p><strong>body_deviation</strong></p> </td> <td> <p>Reports the full body standard deviation score that represents the difference between bone density and the expected value.</p> </td> <td> <p>Numerical. </p> </td> <td> <p>Float value for deviation.</p> </td> </tr> <tr> <td> <p><strong>forearm_deviation</strong></p> </td> <td> <p>Reports the forearm standard deviation score that represents the difference between bone density and the expected value.</p> </td> <td> <p>Numerical. </p> </td> <td> <p>Float value for deviation.</p> </td> </tr> <tr> <td> <p><strong>worst_deviation</strong></p> </td> <td> <p>Reports the worst standard deviation score among all deviations obtained from the record.</p> </td> <td> <p>Numerical. </p> </td> <td> <p>Float value for deviation.</p> </td> </tr> </tbody> </table> <p> </p> <p> </p> </div> <p><strong>REFERENCES</strong><br>Albuquerque, G. et al. A method based on non-ionizing microwave radiation for ancillary diagnosis of osteoporosis: a pilot study. BioMedical Eng. OnLine 21, 70, https://doi.org/10.1186/s12938-022-01038-y (2022).</p> <p>Pinheiro, B. d. M. et al. The influence of antenna gain and beamwidth used in osseus in the screening process for osteoporosis. Sci. Reports 11, 19148, https://doi.org/10.1038/s41598-021-98204-4 (2021).</p> <div> <p> </p> </div>
GAS5 protects against osteoporosis by targeting UPF1/SMAD7 axis in osteoblast differentiation
<p>Osteoporosis is a common systemic skeletal disorder resulting in bone fragility and increased fracture risk. It is still necessary to explore its detailed mechanisms and identify novel targets for the treatment of osteoporosis. Previously, we found that an lncRNA named GAS5 in humans could negatively regulate lipoblast/adipocyte differentiation. However, it is still unclear whether GAS5 affects osteoblast differentiation and whether GAS5 is associated with osteoporosis. Our current research found that GAS5 was decreased in the bones and BMSCs, a major origin of osteoblast, in osteoporosis patients. Mechanistically, GAS5 promotes osteoblast differentiation by interacting with UPF1 to degrade Smad7 mRNA. Moreover, a decreased bone mass and impaired bone repair ability were observed in <em>Gas5</em> heterozygous mice, manifesting in osteoporosis. The systemic supplement of <em>Gas5</em>-overexpressing adenoviruses significantly ameliorated bone loss in an osteoporosis mouse model. In conclusion, GAS5 promotes osteoblast differentiation by targeting the UPF1/Smad7 axis and protects against osteoporosis.</p>
Animal versus plant protein and adult bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation- S1 File
<p>All calculations and meta-analyses for the systematic review "Animal versus plant protein and adult bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation" were conducted in Stata SE 13 (Stata Corp) using this analytical dataset <strong>(S1 File).</strong></p>
OSTEOPOROSIS IN PERIMENOPAUSAL WOMEN. WAYS OF DI-AGNOSIS, CORRECTION AND PREVENTION (LITERATURE REVIEW)
<p><span>Остеопороз,</span><span> как хроническое системное заболевание </span><span>опорно-двигательной системы, снижает прочность костной системы за счёт нарушения обмена веществ и микроархитектоники костей. Это в результате нередко приводит к патологическим переломам. В докладе </span><span>Международной Ассоциации остеопороза говорится, что ежегодно в мире переломы в результате остеопороза встречаются у 30-33% женщин в возрасте старше 50 лет </span></p>
Melatonin Osteoporosis Prevention Study
ClinicalTrials.gov study NCT01152580. IPD Sharing: Not stated. Countries: 1. Publications: 18.
Telemedicine Intention, Need, Expectations, and Perceived Challenges Among Women With Osteoporosis
ClinicalTrials.gov study NCT06969313. IPD Sharing: YES. Countries: 1. Publications: 3.
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
ClinicalTrials.gov study NCT00048074. IPD Sharing: Not stated. Countries: 16. Publications: 1.
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
ClinicalTrials.gov study NCT00541658. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
ClinicalTrials.gov study NCT00808132. IPD Sharing: Not stated. Countries: 12. Publications: 2.
A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.
ClinicalTrials.gov study NCT05338086. IPD Sharing: Not stated. Countries: 8. Publications: 0.
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
ClinicalTrials.gov study NCT00205777. IPD Sharing: Not stated. Countries: 30. Publications: 1.
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
ClinicalTrials.gov study NCT01668589. IPD Sharing: Not stated. Countries: 4. Publications: 1.
A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D
ClinicalTrials.gov study NCT00525798. IPD Sharing: Not stated. Countries: 12. Publications: 1.
Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND
ClinicalTrials.gov study NCT05395091. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
ClinicalTrials.gov study NCT01575834. IPD Sharing: Not stated. Countries: 24. Publications: 17.
Texture Analysis for Postmenopausal Osteoporosis
ClinicalTrials.gov study NCT00145977. IPD Sharing: NO. Countries: 1. Publications: 26.
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
ClinicalTrials.gov study NCT00436917. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis
ClinicalTrials.gov study NCT01992159. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
ClinicalTrials.gov study NCT00086619. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.